CJC-1295 (No DAC) + Ipamorelin (10 mg Blend) Dosage Protocol

Dosing & Reconstitution Overview

This blend pairs CJC-1295 without the Drug Affinity Complex (no DAC) — a modified growth-hormone-releasing-hormone analog — with Ipamorelin, a selective growth-hormone secretagogue. A 10 mg vial typically contains 5 mg of each peptide. The figures below are compiled strictly for laboratory and educational reference; they describe how the compounds were characterised and dosed in published research, not a recommendation for use in humans or animals.

For a 10 mg combined vial, adding 3.0 mL of bacteriostatic water yields a total concentration of roughly 3.33 mg/mL — about 1.67 mg/mL of each peptide (1,667 mcg/mL each). At that fill, every 1 unit (0.01 mL) on a U-100 insulin syringe delivers approximately 33 mcg of each peptide, so a 3-unit draw provides ~100 mcg of each and a 9-unit draw provides ~300 mcg of each.

Standard (Gradual) Titration Schedule

The gradual schedule reflects the conservative dose-escalation pattern common in the secretagogue literature, where the daily amount is stepped up every couple of weeks so that growth-hormone response and tolerability can be assessed at each level before advancing.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until the powder is fully dissolved. Do not shake; vigorous agitation can damage the peptide chains.
4. The solution should be clear and colourless. Label the vial with the total concentration (~3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw each subsequent dose with a fresh sterile syringe.

Conservative Low-Dose Schedule

Where a study design favours a steady, sub-saturation exposure rather than escalation toward the top of the range, a fixed low-dose pattern is sometimes modelled. It holds a single small daily amount throughout, which keeps draw volumes minimal and conserves material across a longer run.

Supplies Needed

• Blend vials (10 mg): ~3 vials for an 8-week run, ~4 vials for 12 weeks, ~5 vials for a 16-week run at daily dosing.
• Insulin syringes (U-100, 30–50 unit): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per draw).
• Bacteriostatic water (10 mL): one bottle covers an 8-week run; two bottles for a 12–16 week run.
• Alcohol swabs: two 100-count boxes for 8–12 weeks; three boxes for a 16-week schedule.

Protocol Overview

• Research goal: model amplified, pulsatile growth-hormone and IGF-1 release via paired GHRH-analog and secretagogue activity.
• Schedule: once-daily subcutaneous administration in the published model.
• Dose band: 100–300 mcg of each peptide per day.
• Fill: 10 mg lyophilized (5 mg + 5 mg), reconstituted to ~3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 100 mcg step and hold each level for one to two weeks before escalating.
• Keep administration on a fixed daily cadence — typically before bed or upon waking — for consistent exposure modelling.
• Dose on an empty stomach where the design allows, since elevated blood glucose and free fatty acids can suppress the growth-hormone pulse.
• Escalate only after tolerability is established at the prior step; the 250–300 mcg band carries the upper-range response in the literature.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, in dry and dark conditions, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within roughly 28 days. Allow refrigerated solution to reach room temperature before drawing to reduce condensation, avoid repeated freeze-thaw cycles, and keep the vial away from light during storage.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Handle the small daily volumes carefully — a 3-unit draw is only 0.03 mL, so air bubbles and dead-space loss matter more here than at larger volumes.
• Keep the stopper intact and wipe it with alcohol before each entry.
• Document each draw — date, volume, remaining material — for reproducibility across the schedule.

How It Works

The two peptides act on complementary pathways to amplify growth-hormone output. CJC-1295 (no DAC) is a modified 29-amino-acid GHRH analog; without the Drug Affinity Complex it has a short half-life, so it raises the amplitude of the body's natural GH pulses rather than producing a flat, continuous elevation, supporting dose-dependent increases in GH and downstream IGF-1.

Ipamorelin is a pentapeptide growth-hormone secretagogue that mimics ghrelin at its receptor, triggering a rapid GH pulse that peaks around 40 minutes after administration with a half-life of roughly 1.5–2.5 hours. It is notably selective, increasing GH without meaningfully raising ACTH, cortisol or prolactin. Used together, the GHRH analog primes the pituitary while the secretagogue triggers release, producing a larger combined pulse than either compound on its own.

Reported Benefits & Side Effects

Effects reported in research

• Sustained elevation of GH and IGF-1 through reinforced pulsatile release patterns.
• Selective GH stimulation from the Ipamorelin component without a measurable cortisol or ACTH rise.
• Once-daily dosing shown to normalise growth in GHRH-deficient animal models.
• Generally well tolerated across the studied dose range.

Side effects reported

• Transient flushing, headache or injection-site reactions in some subjects.
• Reports of increased appetite, mild water retention or tingling sensations.
• Effects are generally mild and tend to settle as exposure continues.

Injection/Handling Technique (Reference Only)

• Clean the vial stopper and the handling site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily, then wait a few seconds before withdrawing the needle.
• Rotate sites systematically — abdomen, thighs, upper arms — to avoid localized tissue changes, and dispose of sharps in an approved container.

References

Related Protocols